{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T06:06:17Z","timestamp":1791525977711,"version":"4.3.4"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","goldjournal.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urology"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.urology.2021.01.021","type":"journal-article","created":{"date-parts":[[2021,1,21]],"date-time":"2021-01-21T17:46:36Z","timestamp":1611251196000},"page":"256-263","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Efficacy and Safety of Vibegron Add-on Therapy in Men With Persistent Storage Symptoms After Receiving Alpha 1-Blocker or Phosphodiesterase 5 Inhibitor: A Preliminary Study"],"prefix":"10.1016","volume":"153","author":[{"given":"Keisuke","family":"Ishikawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Tsujimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miho","family":"Miyoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuto","family":"Miyoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiki","family":"Ogasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ippei","family":"Hiramatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Uesaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiji","family":"Nozaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Shirai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isao","family":"Mitsuhashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sosuke","family":"Sugimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiki","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensho","family":"Noto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Shigeta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Honda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Iwata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeo","family":"Horie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urology.2021.01.021_bib0001","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/S0022-5347(17)49698-4","article-title":"The development of human benign prostatic hyperplasia with age","volume":"132","author":"Berry","year":"1984","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2021.01.021_bib0002","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0090-4295(02)02243-4","article-title":"The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society","volume":"61","author":"Abrams","year":"2003","journal-title":"Urology"},{"key":"10.1016\/j.urology.2021.01.021_bib0003","first-page":"S580","article-title":"Overactive bladder significantly affects quality of life","volume":"6","author":"Abrams","year":"2000","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.urology.2021.01.021_bib0004","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.urology.2011.05.032","article-title":"Survey of overactive bladder symptoms influencing bother before and after treatment with tamsulosin hydrochloride in Japanese patients with benign prostatic hyperplasia","volume":"78","author":"Tsujimura","year":"2011","journal-title":"Urology"},{"key":"10.1016\/j.urology.2021.01.021_bib0005","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1111\/iju.13401","article-title":"Clinical guidelines for male lower urinary tract symptoms and benign prostatic hyperplasia","volume":"24","author":"Homma","year":"2017","journal-title":"Int J Urol"},{"key":"10.1016\/j.urology.2021.01.021_bib0006","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1185\/03007995.2015.1074067","article-title":"Tamsulosin combined with solifenacin versus tamsulosin monotherapy for male lower urinary tract symptoms: a meta-analysis","volume":"31","author":"Gong","year":"2015","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.urology.2021.01.021_bib0007","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1757-5672.2010.00081.x","article-title":"Randomized controlled trial to treat benign prostatic hyperplasia with overactive bladder using an alpha-blocker combined with anticholinergics","volume":"3","author":"Nishizawa","year":"2011","journal-title":"Low Urin Tract Symptoms"},{"key":"10.1016\/j.urology.2021.01.021_bib0008","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.urology.2013.05.008","article-title":"Clinical efficacy and safety of imidafenacin as add-on treatment for persistent overactive bladder symptoms despite alpha-blocker treatment in patients with BPH: the ADDITION study","volume":"82","author":"Takeda","year":"2013","journal-title":"Urology"},{"key":"10.1016\/j.urology.2021.01.021_bib0009","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005493.pub3","article-title":"Botulinum toxin injections for adults with overactive bladder syndrome","author":"Duthie","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.urology.2021.01.021_bib0010","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/nau.22598","article-title":"The efficacy and safety of onabotulinumtoxinA in treating idiopathic OAB: a systematic review and meta-analysis","volume":"34","author":"Cui","year":"2015","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.urology.2021.01.021_bib0011","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1007\/s00192-019-04186-3","article-title":"Posterior tibial nerve stimulation for overactive bladder-techniques and efficacy","volume":"31","author":"Bhide","year":"2020","journal-title":"Int Urogynecol J"},{"key":"10.1016\/j.urology.2021.01.021_bib0012","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/sj.bjp.0706780","article-title":"Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder","volume":"148","author":"Abrams","year":"2006","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.urology.2021.01.021_bib0013","doi-asserted-by":"crossref","first-page":"e18802","DOI":"10.1097\/MD.0000000000018802","article-title":"The efficacy and safety of mirabegron on overactive bladder induced by benign prostatic hyperplasia in men receiving tamsulosin therapy: a systematic review and meta-analysis","volume":"99","author":"Su","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.urology.2021.01.021_bib0014","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1002\/nau.24285","article-title":"A randomized controlled study of the efficacy of tadalafil monotherapy versus combination of tadalafil and mirabegron for the treatment of persistent overactive bladder symptoms in men presenting with lower urinary tract symptoms (CONTACT Study)","volume":"39","author":"Yamanishi","year":"2020","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.urology.2021.01.021_bib0015","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.eururo.2017.12.022","article-title":"Vibegron, a novel potent and selective beta3-adrenoreceptor agonist, for the treatment of patients with overactive bladder: a randomized, double-blind, placebo-controlled phase 3 study","volume":"73","author":"Yoshida","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2021.01.021_bib0016","doi-asserted-by":"crossref","DOI":"10.1111\/bju.15020","article-title":"Efficacy of vibegron, a novel beta3-adrenoreceptor agonist, on severe urgency urinary incontinence related to overactive bladder: post hoc analysis of a randomized, placebo-controlled, double-blind, comparative phase 3 study","author":"Yoshida","year":"2020","journal-title":"BJU Int"},{"key":"10.1016\/j.urology.2021.01.021_bib0017","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1111\/iju.13596","article-title":"Long-term safety and efficacy of the novel beta3 -adrenoreceptor agonist vibegron in Japanese patients with overactive bladder: a phase III prospective study","volume":"25","author":"Yoshida","year":"2018","journal-title":"Int J Urol"},{"key":"10.1016\/j.urology.2021.01.021_bib0018","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1111\/j.1442-2042.2008.02121.x","article-title":"Core Lower Urinary Tract Symptom score (CLSS) questionnaire: a reliable tool in the overall assessment of lower urinary tract symptoms","volume":"15","author":"Homma","year":"2008","journal-title":"Int J Urol"},{"key":"10.1016\/j.urology.2021.01.021_bib0019","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.euf.2019.10.019","article-title":"Mirabegron Add-on therapy to tamsulosin for the treatment of overactive bladder in men with lower urinary tract symptoms: a randomized, placebo-controlled study (MATCH)","volume":"6","author":"Kakizaki","year":"2020","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.urology.2021.01.021_bib0020","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.eururo.2006.09.019","article-title":"Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study","volume":"50","author":"Irwin","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2021.01.021_bib0021","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.urology.2011.02.055","article-title":"Solifenacin as add-on therapy for overactive bladder symptoms in men treated for lower urinary tract symptoms\u2013ASSIST, randomized controlled study","volume":"78","author":"Yamaguchi","year":"2011","journal-title":"Urology"},{"key":"10.1016\/j.urology.2021.01.021_bib0022","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s00345-014-1399-x","article-title":"Add-on anticholinergic therapy for residual nocturia in patients with lower urinary tract symptoms receiving alpha1-blocker treatment: a multi-centre, prospective, randomised study","volume":"33","author":"Yokoyama","year":"2015","journal-title":"World J Urol"},{"key":"10.1016\/j.urology.2021.01.021_bib0023","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1177\/2042098616659412","article-title":"Mirabegron in overactive bladder patients: efficacy review and update on drug safety","volume":"7","author":"Warren","year":"2016","journal-title":"Ther Adv Drug Saf"},{"key":"10.1016\/j.urology.2021.01.021_bib0024","doi-asserted-by":"crossref","first-page":"823","DOI":"10.4140\/TCP.n.2014.823","article-title":"Mirabegron: a Beta-3 agonist for overactive bladder","volume":"29","author":"Bragg","year":"2014","journal-title":"Consult Pharm"},{"key":"10.1016\/j.urology.2021.01.021_bib0025","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/JU.0000000000000807","article-title":"International phase III, Randomized, double-blind, placebo- and active-controlled study to evaluate the safety and efficacy of vibegron in patients with symptoms of overactive bladder: EMPOWUR","volume":"204","author":"Staskin","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2021.01.021_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173096","article-title":"Effects of vibegron, a novel beta3-adrenoceptor agonist, and its combination with imidafenacin or silodosin in a rat with partial bladder outlet obstruction","author":"Maruyama","year":"2020","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.urology.2021.01.021_bib0027","first-page":"1559","article-title":"Efficacy of Tadalafil once daily versus Fesoterodine in the treatment of overactive bladder in older patients","volume":"19","author":"Dell\u2019Atti","year":"2015","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.urology.2021.01.021_bib0028","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nrurol.2011.99","article-title":"The placebo effect in overactive bladder syndrome","volume":"8","author":"Mangera","year":"2011","journal-title":"Nat Rev Urol"}],"container-title":["Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429521000844?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429521000844?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T02:28:21Z","timestamp":1758767301000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090429521000844"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":28,"alternative-id":["S0090429521000844"],"URL":"https:\/\/doi.org\/10.1016\/j.urology.2021.01.021","relation":{},"ISSN":["0090-4295"],"issn-type":[{"value":"0090-4295","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety of Vibegron Add-on Therapy in Men With Persistent Storage Symptoms After Receiving Alpha 1-Blocker or Phosphodiesterase 5 Inhibitor: A Preliminary Study","name":"articletitle","label":"Article Title"},{"value":"Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urology.2021.01.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}